Search details
1.
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Lancet Oncol
; 24(7): 772-782, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37276871
2.
MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
Biochem Biophys Res Commun
; 523(1): 147-152, 2020 02 26.
Article
in English
| MEDLINE | ID: mdl-31836141
3.
Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.
Cancer Med
; 12(4): 4137-4146, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36127767
4.
ORC6, Negatively Regulated by miR-1-3p, Promotes Proliferation, Migration, and Invasion of Hepatocellular Carcinoma Cells.
Front Cell Dev Biol
; 9: 652292, 2021.
Article
in English
| MEDLINE | ID: mdl-34395415
5.
6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming.
Biomed Pharmacother
; 111: 1353-1358, 2019 Mar.
Article
in English
| MEDLINE | ID: mdl-30841449
Results
1 -
5
de 5
1
Next >
>>